ENLT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ENLT is not a clean buy right now for a Beginner-focused, long-term investor with $50,000-$100,000 to deploy. The long-term story is attractive because revenue growth is very strong, guidance was reaffirmed, analysts are lifting targets, and hedge funds are accumulating shares. But the stock just had a sharp negative session after earnings, momentum is weakening, and the latest quarterly earnings quality looks mixed because net income and EPS fell sharply even as revenue surged. For an impatient investor who does not want to wait for a better entry, I would not buy aggressively at this level; I would hold and wait for price strength to return or for a more favorable pullback setup.
Technically, ENLT is in a mixed-to-cautious setup. The moving averages remain bullish with SMA_5 > SMA_20 > SMA_200, which supports the broader uptrend. However, the MACD histogram is below zero and negatively expanding, showing near-term downside momentum. RSI_6 at 40.38 is neutral but leaning weak rather than overbought. Price closed at 85.09, below the pivot of 88.921 and near S1 at 84.978, which suggests the stock is testing support after a heavy drop. The recent pattern projection also points to slightly negative near-term returns, so the short-term trend is weak even though the longer-term structure is still constructive.
["Q1 2026 revenue grew about 54% year over year, showing very strong top-line expansion.", "Adjusted EBITDA came in strong at $154 million, with earnings beat commentary from analysts.", "The company reaffirmed 2026 revenue and EBITDA guidance.", "The U.S. has become Enlight's largest market segment, supporting growth visibility.", "The company began construction on a 475 MW PV phase at CO Bar 3 and expanded its U.S. portfolio to 20 factored GW.", "Enlight raised about $740 million in Q1 and ended with $709 million in cash, improving funding capacity.", "Roth Capital and UBS both raised price targets to $105 and kept Buy ratings.", "Hedge funds are buying, with buying amount up 307.59% over the last quarter."]
["The stock sold off sharply in regular trading, signaling that the market reacted negatively despite the earnings beat.", "MACD is negative and weakening, pointing to short-term downside momentum.", "Net income dropped 74.51% year over year and EPS fell 78.67%, which weakens earnings quality.", "Gross margin declined year over year.", "JPMorgan maintains an Underweight rating, citing valuation concerns.", "No recent insider buying trend is present; insiders are neutral.", "No recent congress trading data is available.", "Short-term pattern analysis suggests slightly negative expected returns over the next day, week, and month."]
Latest quarter: Q1 2026. Financial performance was strong on revenue growth but mixed on profitability. Revenue rose to $199.6 million, up 53.69% year over year, and the company reported a GAAP EPS of $0.16, beating estimates by $0.09. Adjusted EBITDA was strong at $154 million. However, net income fell to $24.1 million, down 74.51% year over year, EPS dropped 78.67%, and gross margin slipped to 52.4%. Overall, the quarter shows excellent growth and scale, but profitability metrics were weaker year over year.
Analyst sentiment is mostly constructive. Roth Capital and UBS both raised price targets to $105 and kept Buy ratings, while Barclays remains Overweight and Deutsche Bank is Hold. JPMorgan is the main bearish voice, raising its target but keeping Underweight due to valuation. The recent trend is clearly toward higher price targets after a strong Q1 beat, which supports a bullish Wall Street pros view on growth and execution, but the cons view is that valuation still limits upside for some firms.
